CSF2 and follicular lymphoma: Simultaneous intranodal administration of the tumor-targeting antibody Rituximab plus autologous dendritic cells plus granulocyte-macrophage colony stimulating factor caused objective clinical responses in 36% of patients with disseminated follicular lymphoma, an aggressive disease with no known cure (116).